Gaucher Disease, Type 3: Clinical Trials

4 trials for Gaucher Disease, Type 3, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated, 1 unknown, 1 withdrawn. 4 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 12Completed 1, Unknown 1
Phase 31Withdrawn 1

Follow Gaucher Disease, Type 3: new trials by email Literature Review of Gaucher Disease, Type 3 trials Research Report on Gaucher Disease, Type 3

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3
Gene therapy, Enzyme Replacement Agent - Gaucher Disease, Type 3
Phase 2 / Phase 3WithdrawnAVROBIO2023-10-012023-08-09
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease
Low-dose CAN103, High-dose CAN103 - Gaucher Disease, Type 1, Gaucher Disease, Type 3
Phase 1 / Phase 2UnknownCANbridge (Suzhou) Bio-pharma Co., Ltd.402022-07-112022-07-27
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
Arimoclomol, Placebo oral capsule - Gaucher Disease, Type 1, Gaucher Disease, Type 3
Phase 2TerminatedZevraDenmark392018-06-062023-01-11
Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
velaglucerase alfa - Gaucher Disease, Type 3
Phase 1 / Phase 2CompletedShire72012-09-142021-06-11

Narrower conditions

Gaucher Disease (4)

Broader conditions

Brain Diseases (4)  ·  Brain Diseases, Metabolic (4)  ·  Brain Diseases, Metabolic, Inborn (4)  ·  Central Nervous System Diseases (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Genetic Diseases, Inborn (4)  ·  Lipid Metabolism Disorders (4)  ·  Lipid Metabolism, Inborn Errors (4)  ·  Lipidoses (4)  ·  Lysosomal Storage Diseases (4)  ·  Lysosomal Storage Diseases, Nervous System (4)  ·  Metabolic Diseases (4)  ·  Metabolism, Inborn Errors (4)  ·  Nervous System Diseases (4)  ·  Nutritional and Metabolic Diseases (4)

Interventions

Enzyme Replacement Therapy (1)  ·  Genetic Therapy (1)  ·  Glucosylceramidase (1)  ·  Velaglucerase alfa, human (1)  ·  arimoclomol (1)  ·  imiglucerase (1)  ·  taliglucerase alfa (1)

Sponsors

AVROBIO (1)  ·  CANbridge (Suzhou) Bio-pharma Co., Ltd. (1)  ·  Shire (1)  ·  ZevraDenmark (1)

Countries

India (2)  ·  China (1)  ·  Egypt (1)  ·  Tunisia (1)

Top investigators

Aabha Nagral, MD (1)  ·  Bing Han, MD (1)  ·  Milena Veselinovic, MD, PhD (1)